RL
Insider
Robert A. Lenz
Head of R&DRobert A. Lenz (Head of R&D) filed 1 Form 4 report in the past 24 months (0 purchases, 1 sale), most often in Neumora Therapeutics, Inc. (NMRA).
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
1
0 buys · 1 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
–
no filings in the window
Last traded
Oct 10 2024
Filed Oct 11 2024
Median ADV $3.2M across their filed names
Open performance→Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 24 months
Most traded names
NMRARecent filings
NMRASALE
Neumora Therapeutics, Inc.
View filing →
–8,260 sh · price not plausible
Exec Oct 10 2024
Filed Oct 11 2024 · 5:30 PM ET NMRASALE Neumora Therapeutics, Inc. View filing → $493K
41,464 sh across 2 lots
Exec Sep 17 2024
Filed Sep 19 2024 · 5:30 PM ET NMRASALE Neumora Therapeutics, Inc. View filing → $377K
32,948 sh × $11.43
Exec Sep 12 2024
Filed Sep 16 2024 · 5:30 PM ET